BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi ...
In a simulated trial, the Florey Dementia Index achieved mean absolute errors of 1.57 and 0.70 years for predicting mild cognitive impairment and Alzheimer's disease onset, respectively ...
Cognitive profiles for early diagnosis of Dementia with Lewy bodies (DLB) have been outlined in a new study, out today in Alzheimer’s & Dementia. Although DLB is the second most common ...
As mental health disorders continue to be a mounting issue both state and nationwide, a new research company working to advance clinical trials for behavioral health indications has opened its doors ...